SAN DIEGO, May 26, 2025 – Meet selectION’s management team for an update on selectION’s best-in-class Kv1.3 ion channel blocker for the treatment of T-cell mediated autoimmunity while maintaining the patients’ full immunocompetence. selectION successfully completed its first-in-human study with si-544 in atopic dermatitis patients, demonstrating excellent safety, tolerability and early efficacy signals. The currently ongoing Phase1b study in psoriasis patients is expected to be completed in Q3 2025, and is designed to evaluate efficacy at high dose level in preparation of subsequent Phase 2 studies.